Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Quantum Private Wealth LLC

Quantum Private Wealth LLC reduced its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 22.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,142 shares of the biopharmaceutical company's stock after selling 8,519 shares during the period. Intra-Cellular Therapies accounts for about 0.8% of Quantum Private Wealth LLC's holdings, making the stock its 24th biggest holding. Quantum Private Wealth LLC's holdings in Intra-Cellular Therapies were worth $2,517,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Wasatch Advisors LP raised its position in shares of Intra-Cellular Therapies by 3.5% during the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company's stock valued at $281,601,000 after buying an additional 130,351 shares during the period. Bellevue Group AG raised its position in Intra-Cellular Therapies by 0.6% in the third quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company's stock valued at $181,873,000 after purchasing an additional 14,342 shares during the period. State Street Corp grew its holdings in shares of Intra-Cellular Therapies by 3.1% during the 3rd quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company's stock worth $136,017,000 after purchasing an additional 56,664 shares during the period. Franklin Resources Inc. lifted its position in Intra-Cellular Therapies by 9.7% in the third quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company's stock valued at $129,463,000 after buying an additional 155,655 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Intra-Cellular Therapies by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,708,301 shares of the biopharmaceutical company's stock worth $125,029,000 after purchasing an additional 22,128 shares during the period. 92.33% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. This trade represents a 4.55 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.60% of the company's stock.

Intra-Cellular Therapies Stock Performance

NASDAQ ITCI traded up $0.64 during trading on Wednesday, reaching $128.60. The company's stock had a trading volume of 2,625,053 shares, compared to its average volume of 4,369,646. The business's fifty day moving average price is $108.45 and its 200-day moving average price is $89.01. Intra-Cellular Therapies, Inc. has a twelve month low of $62.78 and a twelve month high of $128.75. The firm has a market cap of $13.67 billion, a price-to-earnings ratio of -147.81 and a beta of 0.72.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ITCI. Needham & Company LLC reiterated a "hold" rating and set a $100.00 price target on shares of Intra-Cellular Therapies in a research note on Monday, January 13th. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, January 14th. Piper Sandler reaffirmed a "neutral" rating and set a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Baird R W cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Finally, StockNews.com initiated coverage on Intra-Cellular Therapies in a research note on Sunday. They set a "hold" rating for the company. Nine analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Intra-Cellular Therapies presently has an average rating of "Moderate Buy" and an average price target of $103.62.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.